Your search returned 10 results.

Results
	1.	124 I-Nal PET/CT Based 3-D radiobiological dosimetry (3D-RD) for 131I-Nal therapy of metastatic well-differentiated thyroid cancer. MedStar authors: Atkins, Frank Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Year: 2013 Citation: 2013/06/08/ Department: Department of Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Senthamizhchelvan S, Hobbs R, Atkins F, Khorjekar G, Orquiza M, Van Nostrand D, Sgouros G Local accession number: 2013_166 Add to cart (remove)
	2.	Whole body retention of 131I at 24hr versus 48hr as a predictor of maximum tolerated activity (MTA). MedStar authors: Atkins, Frank Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Citation: 2013/06/08/ Department: Medicine/Endocrinology Medicine/Nuclear Medicine Form of publication: Poster Presentation Local accession number: 2013_231 Add to cart (remove)
	3.	124I-NaI PET/CT based 3-D radiobiological Dosimetry (3D-RD) for 131I-NaI therapy of metastatic well-differentiated thyroid cancer. MedStar authors: Atkins, Frank Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Van Nostrand, Douglas Year: 2013 Institution: MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Atkins F, Khorjekar G, Orquiza MD Local accession number: 2013_2 Add to cart (remove)
	4.	Whole body retention of I-131 at 24hr vs. 48hr as a predictor of maximum tolerated activity (MTA). MedStar authors: Atkins, Frank Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Citation: 2013/06/08/ Department: Department of Medicine/Endocrinology Department of Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Atkins F, Van Nostrand D, Orquiza M, Wartofsky L Local accession number: 2013_158 Add to cart (remove)
	5.	I-124 PET quantitation in the presence of I-131 background activity during I-131 therapy: a phantom study. MedStar authors: Atkins, Frank Brown, Taneshea A Moreau, Shari Van Nostrand, Douglas Wu, Di Year: 2017 Citation: Unpublished 2017/10/03 Department: Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Atkins FB Brown TA Frey EC Lodge MA Moreau SL Plyku D Van Nostrand D Wu D Local accession number: A2017_004 Add to cart (remove)
	6.	I-124 PET quantitation in the presence of I-131 background activity during I-131 therapy: a phantom study. MedStar authors: Atkins, Frank Brown, Taneshea A Moreau, Shari Van Nostrand, Douglas Wu, Di Year: 2017 Institution: MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Atkins F Brown T Frey E Lodge M Moreau S Plyku D Van Nostrand D Wu D Local accession number: A2017_428 Add to cart (remove)
	7.	Correlation of 124I PET dosimetry with clinical response of 131I therapy (Tx) for metastatic differentiated thyroid cancer (DTC) MedStar authors: Atkins, Frank Garcia, Carlos Khorjekar, Gauri Mete, Mihriye Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Institution: MedStar Health Research Institute MedStar Washington Hospital Center Washington Cancer Institute Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Khorjekar G, Senthamizhchelvan S, Hobbs R, Orquiza M, Atkins F, Mete M, Garcia C, Wartofsky L, Sgouros G, Van Nostrand D Local accession number: 2013_4 Add to cart (remove)
	8.	Correlation of 124I PET dosimetry with clinical response of 131I therapy (Tx) for Metastatic Differentiated Thyroid Cancer (DTC). MedStar authors: Atkins, Frank Garcia, Carlos Khorjekar, Gauri Mete, Mihriye Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Institution: MedStar Health Research Institute MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Khorjekar G, Orquiza MD, Atkins F, Mete M, Garcia C, Wartofsky L, Van Nostrand D Local accession number: 2013_2 Add to cart (remove)
	9.	Correlation of 124 I PET dosimetry with clinical response of 131 I therapy for metastatic differentiated thyroid cancer. MedStar authors: Atkins, Frank Garcia, Carlos Khorjekar, Gauri Mete, Mihriye Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Institution: MedStar Health Research Institute MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Khorjekar G, Senthamizhchelvan S, Hobbs R, Orquiza M, Atkins F, Mete M, Garcia C, Wartofsky L, Sgouros G, Van Nostrand D Local accession number: 2013_16 Add to cart (remove)
	10.	Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.[Erratum appears in J Nucl Med. 2012 May;53(5):830] MedStar authors: Atkins, Frank B Burman, Kenneth D Chennupati, Shyam P Kharazi, Pejman Khorjekar, Gauri R Mete, Mihriye Moreau, Shari O'Neil, Jeff Van Nostrand, Douglas Wartofsky, Leonard PMID: 22315442 Year: 2012 Citation: Journal of Nuclear Medicine. 53(3):359-62, 2012 Mar. Institution: MedStar Health Research Institute MedStar Washington Hospital Center Department: Medicine/Endocrinology Medicine/Nuclear Medicine Medline publication type: Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins FB, Burman KD, Chennupati SP, Kharazi P, Khorjekar GR, Mete M, Moreau S, O'Neil J, Van Nostrand D, Wartofsky L DOI: http://dx.doi.org/10.2967/jnumed.111.096016 Add to cart (remove)

Powered by Koha